Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
- 22 October 2016
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 161 (1), 83-94
- https://doi.org/10.1007/s10549-016-4026-2
Abstract
Purpose Circulating tumor cell (CTC) is a well-established prognosis predictor for metastatic breast cancer (MBC), and CTC-cluster exhibits significantly higher metastasis-promoting capability than individual CTCs. Because measurement of CTCs and CTC-clusters at a single time point may underestimate their prognostic values, we aimed to analyze longitudinally collected CTCs and CTC-clusters in MBC prognostication. Methods CTCs and CTC-clusters were enumerated in 370 longitudinally collected blood samples from 128 MBC patients. The associations between baseline, first follow-up, and longitudinal enumerations of CTCs and CTC-clusters with patient progression-free survival (PFS) and overall survival (OS) were analyzed using Cox proportional hazards models. Results CTC and CTC-cluster counts at both baseline and first follow-up were significantly associated with patient PFS and OS. Time-dependent analysis of longitudinally collected samples confirmed the significantly unfavorable PFS and OS in patients with ≥5 CTCs, and further demonstrated the independent prognostic values by CTC-clusters compared to CTC-enumeration alone. Longitudinal analyses also identified a link between the size of CTC-clusters and patient OS: compared to the patients without any CTC, those with 2-cell CTC-clusters and ≥3-cell CTC-clusters had a hazard ratio (HR) of 7.96 [95 % confidence level (CI) 2.00–31.61, P = 0.003] and 14.50 (3.98–52.80, P < 0.001), respectively. Conclusions In this novel time-dependent analysis of longitudinally collected CTCs and CTC-clusters, we showed that CTC-clusters added additional prognostic values to CTC enumeration alone, and a larger-size CTC-cluster conferred a higher risk of death in MBC patients.Keywords
Funding Information
- American Cancer Society (123741-RSG-13-003-01-CCE)
- Thomas Jefferson University (5P30CA056036-17)
- Pennsylvania Department of Health (SAP# 4100062221)
This publication has 43 references indexed in Scilit:
- A headlight on liquid biopsies: a challenging tool for breast cancer managementTumor Biology, 2016
- Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapiesPharmacology & Therapeutics, 2015
- Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical UtilityClinical Cancer Research, 2015
- Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer MetastasisCell, 2014
- Molecular analysis of circulating tumour cells—biology and biomarkersNature Reviews Clinical Oncology, 2014
- Circulating tumor cells and DNA as liquid biopsiesGenome Medicine, 2013
- Intratumor Heterogeneity: Evolution through Space and TimeCancer Research, 2012
- Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell LinesPLOS ONE, 2012
- Circulating Tumor Cells as a Window on Metastasis Biology in Lung CancerThe American Journal of Pathology, 2011
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004